• Mashup Score: 0

    Recorded and edited interviews for the “Patient Perspectives: Today’s Unmet Need” session at the 2023 Amyloidosis Forum meeting.

    Tweet Tweets with this article
    • Researchers, life science companies, & other #ATTR #amyloidosis HCPs: What's really important to patients and caregivers? For the #AmyloidosisForum we worked with @MathewMaurer to ask patients how the next phase of #drugdevelopment will impact their lives https://t.co/Jp151XzO7l

  • Mashup Score: 2

    The first generation of drug approvals in #ATTR #amyloidosis has reshaped the research landscape. This month’s hybrid #AmyloidosisForum will consider how to effectively design trials against a backdrop of treatments that slow progression of the disease.

    Tweet Tweets with this article
    • We're delighted last week's #AmyloidosisForum delivered so many great conversations about the future of #ATTR #amyloidosis drug development. We're already hard at work turning those conversations into action! Watch the entire event yourself here: https://t.co/crQV0os656

  • Mashup Score: 3

    The first generation of drug approvals in #ATTR #amyloidosis has reshaped the research landscape. This month’s hybrid #AmyloidosisForum will consider how to effectively design trials against a backdrop of treatments that slow progression of the disease.

    Tweet Tweets with this article
    • 📆🔬💊 We're all set up for tomorrow's #AmyloidosisForum at FDA's White Oak campus (and online via Zoom). All day discussions around #ATTR #amyloidosis drug development. Don't miss out! Register now: https://t.co/R7suiCWCGW https://t.co/KDjkmYmnd4

  • Mashup Score: 1

    The first generation of drug approvals in #ATTR #amyloidosis has reshaped the research landscape. This month’s hybrid #AmyloidosisForum will consider how to effectively design trials against a backdrop of treatments that slow progression of the disease.

    Tweet Tweets with this article
    • We're on our way to DC for tomorrow's #AmyloidosisForum. Can't wait to work with over 60 speakers and push #ATTR #amyloidosis drug development forward! https://t.co/R7suiCWCGW https://t.co/RqssmDmXZ6

  • Mashup Score: 0

    The first generation of drug approvals in #ATTR #amyloidosis has reshaped the research landscape. This month’s hybrid #AmyloidosisForum will consider how to effectively design trials against a backdrop of treatments that slow progression of the disease.

    Tweet Tweets with this article
    • As we get ready for Wednesday's #AmyloidosisForum, we want to take a moment to thank all the supporters that have helped make these conversations about the future of #ATTR #amyloidosis drug development possible! https://t.co/R7suiCWCGW https://t.co/hkiUhzUwTU

  • Mashup Score: 3

    Three men who had heart failure caused by the build-up of sticky, toxic proteins are now free of symptoms after their condition spontaneously reversed in an unprecedented case described by a team at UCL and the Royal Free Hospital.

    Tweet Tweets with this article
    • “Whether these antibodies caused the patients’ recovery is not conclusively proven. However, our data indicates that this is highly likely..." — Julian Gillmore, Head of @UCL Centre for Amyloidosis (and speaker at the #AmyloidosisForum on June 21) https://t.co/yxbII3PkV2

  • Mashup Score: 4

    The first generation of drug approvals in #ATTR #amyloidosis has reshaped the research landscape. This month’s hybrid #AmyloidosisForum will consider how to effectively design trials against a backdrop of treatments that slow progression of the disease.

    Tweet Tweets with this article
    • The first generation of drug approvals in #ATTR #amyloidosis has reshaped the research landscape. This month's #AmyloidosisForum will consider how to effectively design trials against a backdrop of treatments that slow progression of the disease. https://t.co/R7suiCWCGW